BioMarin Pharmaceutical | BMRN - Ebitda



金融业
股票价格
USD
资产
USD 11.72B
现金及等价物
USD 874.01M
销售成本
USD 276.29M
流动资产
USD 3.97B
流动负债
USD 1.66B
债务
USD 1.44B
EBIT
USD 105.61M
EBITDA
USD 146.05M
员工
3.04K
EPS每股收益
USD 1.2
股本和储备
USD 6.32B
销售毛利
USD 713.42M
债务利息支出
USD 63.3M
利息收入
USD 22.56M
贷款资金
USD 3.53B
市值
USD 12.24B
净收入
USD 44.76M
营业费用
USD 6.32B
营业利润
USD 105.61M
普通股股本
USD 193.54M
PE价格收益
21.07
税前利润
USD 141.2M
销售收入
USD 990M
销售和管理费用
USD 395.55M
股票
USD 1.78B
贸易债权人
USD 913.67M
应收帐款人
USD 1.06B


Ebitda 更改 日
Acadia Pharmaceuticals USD -1.62M 21.94M 2026-03
Agios Pharmaceuticals USD -108.66M 11.65M 2026-03
Alnylam Pharmaceuticals USD 245.34M 59.15M 2026-06
Amgen USD 3.86B 1.28B 2026-03
Bayer EUR 2.14B 2.31B 2026-06
Biogen USD 649.7M 76.5M 2026-03
BioMarin Pharmaceutical USD 146.05M 170.22M 2026-03
Gilead Sciences USD 3.51B 489M 2026-03
Incyte USD 778.57M 410.6M 2026-06
Insmed USD -148.3M 165.88M 2026-03
Ionis Pharmaceuticals USD -64.53M 135.49M 2026-03
Moderna USD -1.26B 468M 2026-03
Neurocrine Biosciences USD 193.3M 25.1M 2026-03
PTC Therapeutics USD 61.98M 132.97M 2026-03
Puma Biotechnology USD 729K 11.36M 2024-06
Regeneron Pharmaceuticals USD 1.66B 695.2M 2026-06
Roche Holding CHF 13.43B 744M 2026-06
Sanofi EUR 2.72B 2.94B 2026-03
Sarepta Therapeutics USD 375.48M 627.68M 2026-03
Ultragenyx Pharmaceutical USD -155M 55.57M 2026-03
United Therapeutics USD 355M 11.1M 2026-06
Vertex Pharmaceuticals USD 1.33B 130.5M 2026-06